Advertisement

Topics

'Keep a Close Eye On' This Regenerative Medicine Firm

02:00 EDT 18 Aug 2017 | InvestorIdeas

August 18, 2017 (Investorideas.com Newswire) In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection."

Original Article: 'Keep a Close Eye On' This Regenerative Medicine Firm

NEXT ARTICLE

More From BioPortfolio on "'Keep a Close Eye On' This Regenerative Medicine Firm"

Advertisement
Quick Search
Advertisement
Advertisement